So when people post misinformation and pseudoscience on here I shouldn't call it out? People need to know that finasteride is not a "tranny drug". Think about why Tom posts here? If I wasn't treating my hair loss I wouldn't be on this site. Since he doesn't believe in treatment why is he here? His only purpose for being here is to scare people away. I'm here to learn about treating hair loss, and help others do the same. The people who come on here trying to stop us from doing that are toxic, and you may be happy to sit on the sidelines and let them get away with it, but I'm not. If you think that's toxic, too bad. I'm going to call out bs when I see it.
Lmao, damn this one is more delusional than that @Haironnu guy. Here i'l leave this here so you can read it again, the studies and meta analysis made by "lawyers" lmao
Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
Abstract
IMPORTANCE:
Two meta-analyses conclude that finasteride treatment of androgenic alopecia (Androgenetic Alopecia) is safe but do not assess quality of safety reporting.
OBJECTIVE:
To assess safety reporting for clinical trial reports of finasteride for Androgenetic Alopecia.
DATA SOURCES:
MEDLINE, ClinicalTrials.gov, and a clinical data repository for an academic medical center.
STUDY SELECTION:
Published clinical trial reports for finasteride treatment of Androgenetic Alopecia.
DATA EXTRACTION AND SYNTHESIS:
For each trial, we assessed quality of adverse event reporting, extracted the number and type of adverse events in treatment and placebo groups, and assessed duration of safety evaluation and adequacy of blinding. Two observers independently extracted the data; differences were resolved by consensus. We assessed generalizability in a large cohort of men prescribed finasteride, 1.25 mg/d or less, by assessing for eligibility in the finasteride-Androgenetic Alopecia pivotal trials.
MAIN OUTCOMES AND MEASURES:
Quality was assessed as adequate, partially adequate, inadequate, or no events reported. We used funnel plots of the hazard ratio to assess bias.
RESULTS:
Of 34 clinical trials, none had adequate safety reporting, 19 were partially adequate, 12 were inadequate, and 3 reported no adverse events. Funnel plots were asymmetric with a bias toward lower odds ratio for sexual adverse effects, suggesting systematic underdetection. No reports assessed adequacy of blinding, 18 (53%) disclosed conflicts of interest, and 19 (56%) received funding from the manufacturer. Duration of drug safety evaluation was 1 year or less for 26 of 34 trials (76%). Of 5704 men in the clinical data repository who were treated for Androgenetic Alopecia with finasteride, 1.25 mg/d or less, for Androgenetic Alopecia, only 31% met inclusion criteria for the pivotal trials referenced in the manufacturer's full prescribing information and 33% took finasteride for more than 1 year.
CONCLUSIONS AND RELEVANCE:
Available toxicity information from clinical trials of finasteride in men with Androgenetic Alopecia is very limited, is of poor quality, and seems to be systematically biased. In a cohort of men prescribed finasteride for routine treatment of Androgenetic Alopecia, most would have been excluded from the pivotal studies that supported US Food and Drug Administration approval for Androgenetic Alopecia. Published reports of clinical trials provide insufficient information to establish the safety profile for finasteride in the treatment of Androgenetic Alopecia.
The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064044/
Last edited: